Alleo Labs is a biotech startup leveraging AI to advance precision medicine for sporadic neurodegeneration. Focused on reducing neuroinflammation and other pathologies, Alleo is developing first-in-class, selective deubiquitinase inhibitors for treating Alzheimer’s (AD) and Parkinson’s (PD) patient subtypes. There is increasing evidence that both AD and PD are better defined as syndromes than single diseases. Leveraging patient data, we employ a suite of in-house computational frameworks for stratifying patient populations, characterizing disease mechanisms, and identifying novel AD and PD targets to develop precision therapies.

Biology: Our primary program ALO-001 is for a preclinical program aimed at reducing α-synuclein and inflammation in PD patients. We are developing small-molecule inhibitors against a novel undisclosed deubiquitinase target validated in preclinical Parkinson’s models, including mice expressing the mutant human A53T α-synuclein, demonstrating that knockdown of the deubiquitinase target has the potential to improve survivability and motor symptoms as well as reduce α-synuclein and Type I Interferon signaling. Additionally, our ALO-002 program is aimed at treating patient subtypes with sporadic AD.